Lymphoma patients treated with anti-CD20 and chemotherapy display disconnected T and B cell responses to COVID-19 vaccine

Lymphoma patients treated with anti-CD20 and chemotherapy display disconnected T and B cell responses to COVID-19 vaccine

Due to immunosuppressive treatment, COVID-19 vaccination is challenging in patients with B-cell lymphoma. We prospectively evaluated CD4, CD8 T-cell and serological responses to the COVID-19 mRNA vaccine in a cohort of patients treated for a B-cell lymphoma with anti-CD20 therapy. During lymphoma tr...

Full description

Saved in:
Bibliographic Details
Main Authors: Sylvain Lamure, Houria Hendel Chavez, Marie-Ghislaine de Goër de Herve, Luc-Matthieu Fornecker, Bernard Drenou, Caroline Jacquet, Fatiha Merabet, Milena Kohn, Florence Quélin, Angela Jackson, Sylvain Choquet, Rémy Duléry, Yassine Taoufik, Caroline Besson
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Immunology
Subjects:
COVID-19 vaccine
lymphoma
immune response
anti-CD20
chemotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1524813/full
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Due to immunosuppressive treatment, COVID-19 vaccination is challenging in patients with B-cell lymphoma. We prospectively evaluated CD4, CD8 T-cell and serological responses to the COVID-19 mRNA vaccine in a cohort of patients treated for a B-cell lymphoma with anti-CD20 therapy. During lymphoma treatment, CD4, CD8, and CD19 cell dropped. While functional-specific CD4 and CD8 T-cell responses to SARS-CoV-2 were unaffected, vaccination in patients on treatment induced low specific antibody titers, contrasting with a preserved serological response when vaccination was completed before treatment initiation. Those findings reinforce a vaccinal strategy based on completion before lymphoma treatment, with a booster administered afterward.
ISSN:1664-3224

Similar Items